The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical impact of gastric acid suppressing medication use on the efficacy of elrotinib and gefitinib in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Yoshitaka Zenke
No relevant relationships to disclose
Kiyotaka Yoh
Consultant or Advisory Role - AstraZeneca (U)
Honoraria - AstraZeneca; Chugai Pharma
Shingo Matsumoto
Honoraria - Chugai Pharma
Shigeki Umemura
Research Funding - Chugai Pharma
Seiji Niho
Honoraria - AstraZeneca; Chugai Pharma
Koichi Goto
Consultant or Advisory Role - Chugai Pharma (U)
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - AstraZeneca; Chugai Pharma
Hironobu Ohmatsu
No relevant relationships to disclose
Yuichiro Ohe
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - AstraZeneca; Chugai Pharma